CCL2 and neoplasm: For example, preclinical studies showed that targeting CCL2 or the CCL2 receptor (CCR2) on tumor infiltrating macrophages improved chemotherapeutic efficacy, inhibited metastasis and increased anti-tumor T-cell responses [72, 250, 251].